Stapler Surgery for Hemorrhoids (PPH — Procedure for Prolapse and Hemorrhoids) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Stapled hemorrhoidopexy — commercially known as PPH (Procedure for Prolapse and Hemorrhoids) and colloquially as the Longo procedure (after its inventor, Italian surgeon Antonio Longo, 1998) — is a minimally invasive surgical technique for the definitive treatment of Grade III and IV prolapsed internal hemorrhoids. Rather than excising the hemorrhoidal tissue itself (as in conventional Milligan-Morgan or Ferguson hemorrhoidectomy), PPH removes a circumferential ring of prolapsed rectal mucosa and submucosa approximately 4 cm above the dentate line, using a purpose-designed circular stapling device. This repositions ("pexy") the prolapsed hemorrhoidal cushions back to their anatomical position within the anal canal while simultaneously interrupting the superior hemorrhoidal arterial blood supply, causing the hemorrhoidal tissue to shrink.

The critical advantage of this approach is that the resection and anastomosis occur entirely above the dentate line — in the insensate transitional zone of the rectum — rather than in the sensitive squamous epithelium of the lower anal canal where conventional hemorrhoidectomy wounds are placed. This results in dramatically reduced post-operative pain, shorter hospital stay, and faster return to normal activities compared to excisional techniques.

The procedure uses a PPH03 or PPH01 circular stapler (Ethicon Endo-Surgery / Johnson & Johnson) — a 33-mm circular stapler with a built-in tissue knife and two staggered rows of titanium staples, producing a stapled anastomosis as the staple cartridge fires. The PPH01 is the original device; PPH03 is the third-generation design with improved staple geometry and a more ergonomic handle. Competing devices include the Proximate PPH, Covidien EEA, and Grena Hemorrhoid Stapler.

PPH is performed under spinal or general anaesthesia as a day-case or short-stay (23-hour) procedure. It has been adopted worldwide as a standard surgical option for appropriate hemorrhoidal disease, with over 1 million procedures performed globally since its introduction. Careful patient selection is paramount to optimising outcomes and minimising the specific complications of the technique.

Stapled hemorrhoidopexy is indicated for a specific subset of hemorrhoidal and anorectal conditions:

• Grade III internal hemorrhoids: Hemorrhoids that prolapse on straining but require manual reduction. This is the primary and most common indication for PPH. The prolapsed mucosa is amenable to circumferential excision and repositioning. Patient satisfaction is high when selection is appropriate.
• Grade IV internal hemorrhoids: Permanently prolapsed hemorrhoids that cannot be manually reduced. PPH can be performed, though recurrence rates are higher than for Grade III disease, and some colorectal surgeons prefer conventional excisional hemorrhoidectomy for Grade IV disease, particularly when there is a large external hemorrhoidal component.
• Mucosal prolapse: Circumferential rectal mucosal prolapse without a true full-thickness rectal prolapse is amenable to PPH, as the procedure addresses redundant mucosal tissue and restores normal anatomy. Full-thickness rectal prolapse (procidentia) is not an indication for PPH.
• Circumferential hemorrhoidal disease: Multiple simultaneous hemorrhoidal columns (typically at the 3, 7, and 11 o'clock positions when viewed in the lithotomy position) are addressed simultaneously in a single firing of the circular stapler, unlike conventional hemorrhoidectomy where each column is excised individually — reducing operating time and the risk of anal stenosis from multiple wounds.
• STARR/STARRPLUS (Stapled Trans-Anal Rectal Resection): An extension of the PPH technique developed for obstructed defecation syndrome (ODS), where rectocele and/or internal rectal intussusception cause difficulty with complete rectal evacuation. STARR uses two PPH or Contour Transtar devices fired sequentially (anterior and posterior walls) to resect a full-thickness cylinder of distal rectum. The STARRPLUS system uses a single dedicated device. STARR is not a hemorrhoid treatment per se, but shares the circular stapler platform with PPH.

Important exclusions: PPH is not indicated for predominantly external hemorrhoids (which remain untreated), thrombosed external hemorrhoids, Grade I–II internal hemorrhoids (appropriately managed by banding or sclerotherapy), or patients with inflammatory bowel disease involving the anorectum.

Careful patient selection is the key to achieving good outcomes with PPH and avoiding its specific complications:

• Ideal candidate: A patient with symptomatic Grade III internal hemorrhoids (bleeding, prolapse requiring manual reduction, mucus discharge, soiling) who has failed conservative management (dietary fibre, topical treatments, rubber band ligation, sclerotherapy) and has predominantly internal or circumferential prolapsed hemorrhoidal disease without a large external component.
• Grade IV disease: Can be treated with PPH but recurrence rates are higher. Patients should be counselled that re-operation rates are 10–15% over 5 years and that conventional hemorrhoidectomy has lower long-term recurrence rates (<5%) at the cost of greater post-operative pain and longer recovery.
• Exclusion — external hemorrhoids: PPH does not excise external hemorrhoid skin tags or thrombosed external hemorrhoids; these remain and may require separate treatment. Patients presenting primarily for cosmetic improvement of external skin tags are not good PPH candidates.
• Previous anorectal surgery: Prior hemorrhoidectomy, anal fistula surgery, or sphincterotomy may affect tissue mobility and stapler placement. Assessment by an experienced colorectal surgeon is essential.
• Anorectal anatomy assessment: Pre-operative examination under anaesthesia (EUA) or anorectal manometry may be performed in patients with suspected low anterior sphincter pressure, which could predispose to urgency or incontinence following PPH (from anastomosis at the level of the internal sphincter).
• Medical fitness: Patients on anticoagulants must have INR in therapeutic range adjusted pre-operatively. Antiplatelet agents are generally stopped 5–7 days before surgery in liaison with the prescribing physician. Active ano-rectal infection is a contraindication to elective PPH.

The PPH procedure follows a standardised technique with minor variations between surgeons and between the PPH01 and PPH03 device generations:

• Anaesthesia and positioning: Spinal anaesthesia is preferred for its reliable perineal muscle relaxation, post-operative analgesia (reducing early pain scores), and avoidance of general anaesthesia risks. The patient is positioned in the lithotomy (most common) or prone Jack-knife position depending on surgeon preference.
• Dilatation and proctoscopy: The PPH circular anal dilator (CAD33) is inserted and secured with stay sutures to the perianal skin. The obturator is removed to reveal the prolapsed hemorrhoidal mucosa. A purse-string suture anoscope (PSA33) is introduced to delineate the purse-string suture placement level — 4 cm above the dentate line in the rectal mucosa and submucosa.
• Purse-string suture (PSS): A 2/0 or 0 polypropylene or prolene monofilament purse-string suture is placed circumferentially at 4 cm above the dentate line, incorporating only mucosa and submucosa (not muscularis propria). The depth and completeness of this suture is the most technically demanding step and the principal determinant of a symmetrical, adequate mucosal resection.
• Stapler insertion and firing: The PPH03/PPH01 circular stapler is fully opened, inserted through the dilator, and the anvil is positioned above the purse-string suture. The suture ends are tied and brought through the lateral holes of the stapler shaft, gently tensioning the mucosal prolapse into the stapler cartridge. After confirming that the vaginal posterior wall (in women) has not been incorporated (digital check), the stapler is closed and fired, simultaneously cutting and stapling a 2.5 cm wide ring of prolapsed mucosa and creating a stapled anastomosis.
• PPH03 vs PPH01: The PPH03 device features a redesigned shaft for easier insertion, modified anvil for more uniform tissue incorporation, and ergonomic safety handle. Both devices achieve equivalent resection and anastomosis; PPH03 is the current commercial standard in most markets.
• Haemostasis check: The fired staple ring (donut) is inspected for completeness. Haemostasis of the staple line is checked with a suture proctoscope; any bleeding points are sutured with 2/0 Vicryl figure-of-8 sutures. A rectal pack is left in situ for 15 minutes post-firing before final haemostasis check.

The PPH procedure offers compelling advantages over excisional hemorrhoidectomy in appropriately selected patients, supported by Level 1 evidence from multiple randomised controlled trials and systematic reviews:

• Significantly less post-operative pain: Because the resection and anastomosis occur above the dentate line in the insensate rectal mucosa (not the pain-sensitive squamous epithelium of the anoderm), post-operative pain scores are substantially lower than with excisional hemorrhoidectomy. Multiple meta-analyses consistently demonstrate significantly lower visual analogue scale (VAS) pain scores at 24 hours, 1 week, and 2 weeks post-operatively.
• Faster return to normal activity: Patients undergoing PPH return to work and normal daily activities in approximately 7 days, compared to approximately 14 days for conventional Milligan-Morgan hemorrhoidectomy. This productivity benefit is a major driver of patient preference for the stapled technique.
• Shorter hospital stay: PPH is performed as a day-case (discharge same day) or 23-hour admission in most patients, compared to 1–3 night stays with conventional hemorrhoidectomy. NHS Health Technology Assessment data confirm PPH has lower total hospital costs per episode despite higher device costs.
• Less analgesic requirement: Post-operative opioid requirement is significantly lower after PPH, reducing opioid-related side effects (nausea, constipation, sedation) and facilitating earlier discharge.
• Single-stage treatment of circumferential disease: The circumferential staple line addresses multiple hemorrhoid columns simultaneously, unlike conventional three-column hemorrhoidectomy which creates three separate wounds — each with attendant pain and healing time.
• Lower wound care burden: The internal staple-line anastomosis does not require the wound packing, daily dressing changes, and prolonged sitz baths needed for open excisional wounds in Milligan-Morgan hemorrhoidectomy.

While PPH offers important advantages, it carries specific complications that differ from those of excisional surgery and should be discussed in full during the consent process:

• Higher recurrence rate: The most significant long-term disadvantage of PPH compared to excisional hemorrhoidectomy. Cochrane systematic reviews and the UK MRC eTHoS trial (Excisional versus Stapled Treatment for Hemorrhoids) demonstrate recurrence rates of 10–15% at 1–3 years for PPH versus <5% for excisional hemorrhoidectomy. This difference is most pronounced for Grade IV disease. Patients must be counselled that re-treatment may be needed.
• Residual external hemorrhoids and skin tags: PPH does not excise external hemorrhoidal tissue. External skin tags remain and may continue to cause hygiene difficulties or cosmetic concern. Patients presenting primarily for cosmetic improvement of external disease may be dissatisfied with PPH outcomes.
• Anastomotic stricture: Circumferential stapling can result in fibrotic scarring and stenosis at the anastomotic line in 1–5% of cases, causing difficulty with defaecation, incomplete evacuation, or pain. Mild strictures are managed with anal dilators; severe cases require surgical division under anaesthesia.
• Solitary rectal ulcer syndrome (SRUS) / staple line ulceration: An uncommon but recognised complication in which a non-healing ulcer develops at or near the staple line, associated with ongoing bleeding, mucus discharge, and tenesmus. This may represent impaired healing due to ischaemia, tension on the anastomosis, or recurrent internal intussusception. Management is complex and may require endoscopic or surgical intervention.
• Urgency and faecal incontinence: Reported in a small proportion of patients, possibly due to anastomosis at the level of the internal anal sphincter causing mechanical or sensory effects. Usually transient; permanent incontinence is rare (<1%) but has been reported in case series.
• Pelvic sepsis: A rare but potentially life-threatening complication (<0.1%) if a staple line dehiscence occurs with contamination of the perirectal space. Presents with severe perineal or lower abdominal pain, fever, and tachycardia days post-operatively. Requires urgent imaging (CT pelvis) and surgical drainage. Early recognition is critical.
• Rectal perforation / rectovaginal fistula: Rare complications (<0.1%) from inadvertent incorporation of the posterior vaginal wall (in women) into the staple line, or from stapler misfiring. Meticulous pre-firing posterior vaginal wall check is mandatory.

Post-operative management after PPH differs from conventional hemorrhoidectomy in several key respects, reflecting the different wound type and complication profile:

• Immediate recovery: A rectal pack (usually Kaltostat or gauze) is placed at the end of surgery and removed in the recovery area after 2–4 hours or at discharge. Spinal anaesthesia typically provides 4–6 hours of post-operative analgesia, after which oral analgesia (paracetamol + ibuprofen + codeine phosphate) is commenced.
• Dietary and bowel advice: A high-fibre diet (25–35 g/day) and adequate fluid intake (2–2.5 L/day) are prescribed from the day of surgery to prevent constipation, which is the principal risk factor for anastomotic tension and bleeding. Osmotic laxatives (lactulose, macrogol) are prescribed for the first 4–6 weeks.
• Warning signs requiring urgent review: Patients are instructed to present immediately to the emergency department for: bright red rectal bleeding more than a teaspoon in volume; severe abdominal or perineal pain out of proportion to expectation; fever >38.5°C; inability to pass urine; or swelling and crepitus of the perineum (signs of necrotising fasciitis — exceedingly rare but catastrophic if missed).
• 6-week post-operative review: Outpatient review at 6 weeks with digital rectal examination and proctoscopy to confirm anastomotic healing, absence of stricture, and resolution of hemorrhoidal prolapse. Patients with ongoing symptoms (incomplete evacuation, urgency, mucus discharge) require further evaluation including anorectal manometry and colonoscopy if indicated.
• Long-term surveillance: Annual review for the first 3 years for patients at higher recurrence risk (Grade IV disease, large external component, incomplete purse-string suture at original operation). Recurrent prolapse or hemorrhoidal symptoms can be managed with repeat banding in the outpatient department, or re-do PPH or conventional hemorrhoidectomy in the operating theatre.

The economic case for PPH versus conventional hemorrhoidectomy is nuanced and depends on the healthcare system and time horizon considered:

• Device cost: The PPH03 stapler cartridge (single-use) costs approximately USD 250–450 (ex-factory) or GBP 200–350 in the UK. This is significantly more expensive than the basic instruments used for conventional hemorrhoidectomy, representing the principal cost disadvantage of the stapled technique. The CAD33 dilator and PSA33 anoscope components are included in the kit.
• Procedure and hospital costs: Despite the higher device cost, NHS Health Technology Assessment analyses demonstrate that total in-hospital costs for PPH are comparable to or marginally lower than conventional hemorrhoidectomy when shorter operative time, earlier discharge, and lower post-operative nursing requirements are factored in. Day-case PPH (same-day discharge) substantially reduces total episode costs.
• Productivity and indirect costs: The 7-day return to work versus 14 days for conventional hemorrhoidectomy represents a significant indirect cost advantage — valued at GBP 500–1,500 per patient in UK health economic analyses, and proportionally more in higher-income economies. This benefit is particularly relevant for self-employed patients and those without paid sick leave.
• Country-specific costs: India (private tertiary hospitals): INR 35,000–80,000 (USD 420–960) all-inclusive. UK (NHS): Free on referral; private: GBP 2,500–4,500. USA: USD 5,000–12,000 (including anaesthesia and ambulatory surgery centre facility fee). Germany: EUR 3,500–6,000. India is a popular medical tourism destination for PPH given the favourable cost-to-quality ratio at NABH-accredited colorectal surgery centres.
• Recurrence costs: The higher recurrence rate of PPH (10–15% vs <5% for excisional) means a proportion of patients incur re-treatment costs within 3–5 years. When these downstream costs are incorporated into lifetime cost modelling, the economic advantage of PPH over conventional hemorrhoidectomy narrows, and some analyses favour conventional hemorrhoidectomy for Grade IV disease where recurrence risk is highest.

A range of surgical and non-surgical alternatives to PPH exist across the spectrum of hemorrhoid severity:

• Conventional excisional hemorrhoidectomy (Milligan-Morgan / Ferguson): The gold-standard surgical treatment for all grades of hemorrhoidal disease, with recurrence rates below 5% at 10 years — the lowest of any surgical technique. The Milligan-Morgan (open) technique leaves the excision wounds open to heal by secondary intention; the Ferguson (closed) technique sutures the wounds primarily. Both are associated with significantly more post-operative pain and longer recovery (return to work: ~14 days) than PPH, but offer superior long-term durability, complete treatment of external hemorrhoidal disease, and lower rates of urgency and stricture.
• Rubber band ligation (RBL): First-line office procedure for Grade I–III internal hemorrhoids. A rubber band is placed at the base of each hemorrhoidal column above the dentate line, causing ischaemic necrosis and fibrotic fixation of the hemorrhoid. RBL is highly effective (70–80% success for Grade II–III after 1–3 sessions), virtually painless when placed correctly, cheap, and repeatable. It is the preferred non-surgical treatment before escalating to PPH or excisional hemorrhoidectomy.
• Sclerotherapy: Injection of a sclerosant (phenol in oil, sodium tetradecyl sulphate) into the submucosal plane above the hemorrhoid, causing fibrotic fixation. Appropriate for Grade I–II bleeding hemorrhoids, particularly in anticoagulated patients who cannot stop medications for banding. Less effective than RBL for prolapsed hemorrhoids.
• Haemorrhoidal Artery Ligation and Recto-Anal Repair (HAL-RAR / HALO): A Doppler-guided transanal technique in which the terminal branches of the superior hemorrhoidal artery are ligated (6–8 sutures), reducing blood flow to the hemorrhoidal cushions, combined with mucopexy sutures to reposition prolapsed tissue. HAL-RAR avoids excision and stapling entirely, resulting in minimal post-operative pain and rapid recovery. Recurrence rates are 10–15% at 1 year — similar to PPH — making it an alternative for Grade III hemorrhoids in patients who wish to avoid stapling devices. The HALO device (AMI GmbH) is the market leader.
• Transanal Hemorrhoidal Dearterialisation (THD): Similar to HALO/HAL-RAR; uses ultrasound Doppler to identify and ligate hemorrhoidal arteries with mucopexy. Equivalent outcomes to HALO with low pain scores.
• Conservative management: For Grade I–II hemorrhoids: high-fibre diet (25–35 g/day soluble and insoluble fibre), adequate hydration, avoiding prolonged straining on the toilet, sitz baths (warm water soaks for 10–15 minutes after bowel movements), and topical preparations (lidocaine, hydrocortisone, witch hazel) for symptom relief. Many patients with Grade I–II hemorrhoids are managed definitively without any procedural intervention.